SEC Form 4 · accession 0001609351-17-000011
Spark Therapeutics, Inc. · ONCE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Katherine A High
Officer — See Remarks · Director
Period of report
Jan 18, 2017
Accepted (ET)
Jan 20, 2017 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609351
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $56.17 | Jan 18, 2017 | A | 31,500 | A | — | Jan 17, 2027 | Common Stock | 31,500 | 31,500 | D |
| Restricted Stock UnitsF2,F3 | — | Jan 18, 2017 | A | 9,000 | A | — | — | Common Stock | 9,000 | 18,000 | D |
Explanation of responses
- F125% vests January 18, 2018 and the remainder vests in equal annual installments over the following three years.
- F2Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics common stock.
- F3The restricted stock units vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date.
Remarks
President and Chief Scientific Officer